International GrowthChina grew 12% in the third quarter, driven by strength in Pharma and Academia, with local biotech's re-accelerating and benefiting from increased collaboration with multinationals.
Revenue GrowthWAT's ability to operate and price their way to more revenue synergies, and that initial cost-out projections look very de-risked.
Software ExpansionGLP-1 volume uplift and Empower software expansion may be underappreciated in Street models, with potential for revenue to double again next year.